Demyelination may not be good indicator of MS progression, study finds

A study by researchers from Queen Mary University of London establishes for the first time the extent of neuronal loss in the brain of a person with MS over their life, and finds that demyelination may not be as good an indicator of disease progression as previously thought.

By dissecting and analyzing brains from nine people with MS and seven healthy controls using gold standard techniques, they found that the mean number of neurons was 14.9 billion in MS versus 24.4 billion in controls - a 39% difference.

The density of neurons in MS was smaller by 28%, and cortical volume by 26%, and they found that the whole brain was affected equally.

Importantly, the number of neurons was strongly associated with the thickness of the cortex, which is something that can be measured by MRI. The decline in volume of the cortex could therefore be detected in vivo and be used to predict neuronal loss in patients or measure neurodegeneration during clinical trials.

Lead researcher Klaus Schmierer said: "Given that we found no association between neuronal loss and demyelination, trying to detect demyelinating lesions in the cortex - an area of research strongly driven by the availability of high field MRI systems - may be of lesser importance than measuring cortical volume and getting on with early active treatment."

As cortical neuronal loss is responsible for cognitive and other functions, which occur early in MS, the researchers say that to avoid neurodegeneration, early treatment is key.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Special MRI technique predicts onset of mild cognitive impairment and cognitive decline